SRR6013587
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.560
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- G2M_CHECKPOINT+0.510
- PANCREAS_BETA_CELLS+0.490
- ANGIOGENESIS+0.430
- MITOTIC_SPINDLE+0.270
- MTORC1_SIGNALING+0.240
- SPERMATOGENESIS+0.230
- MYC_TARGETS_V1+0.220
- HYPOXIA+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.420
- INTERFERON_GAMMA_RESPONSE-0.340
- APICAL_SURFACE-0.320
- P53_PATHWAY-0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
- ADIPOGENESIS-0.240
- ALLOGRAFT_REJECTION-0.220
- HEME_METABOLISM-0.200
- IL6_JAK_STAT3_SIGNALING-0.200
- TNFA_SIGNALING_VIA_NFKB-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 65460 | EPN | Supratentorial EPN | 0.758 |
| 2 | SRR1516047 | — | — | 0.742 |
| 3 | c45adda2-fffe-4add-8148-01ecf35dd855 | — | — | 0.738 |
| 4 | TCGA-33-4533-01A-01R-1201-07 | — | cohortMD1 | 0.733 |
| 5 | SRR1313155 | — | E | 0.724 |
| 6 | TCGA-GV-A3JZ-01A-11R-A21D-07 | — | — | 0.716 |
| 7 | 20110025.TNBC | — | E | 0.709 |
| 8 | MBCProject_2290_T2_RNA | — | E | 0.709 |
| 9 | SRR8518398 | — | E | 0.707 |
| 10 | TCGA-CV-7102-01A-11R-2016-07 | — | — | 0.706 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.490 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.110 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |